Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk

  • Roberto Vettor | roberto.vettor@unipd.it Internal Medicine 3, Endocrine-Metabolic Laboratory, Department of Medicine DIMED, University of Padova, Padova, Italy.
  • Roberto Serra Internal Medicine 3, Endocrine-Metabolic Laboratory, Department of Medicine DIMED, University of Padova, Padova, Italy.

Abstract

Hypercholesterolemia is a major risk factor for cardiovascular disease (CVD). Lowering low-density lipoproteins-cholesterol (LDL-C) has been shown to decrease the risk of CVD and of all-cause mortality. For appropriate management, estimation of each individual’s total cardiovascular risk is critical, as patients should receive treatment according to their cardiovascular risk category as well as their LDL-C level. However, available data indicate that a large proportion of patients fail to achieve lipid goals despite treatment, and a significant percentage of patients are not able to tolerate statin treatment. Researchers have therefore focused considerable attention on the development of novel LDL-C-lowering agents that act via different mechanisms. Among the most recent advances in clinical development are the proprotein convertase subtilisin/kexin 9 antibody inhibitors, including alirocumab and evolocumab, which appear particularly promising, with clinical trial data indicating these agents to be both well tolerated and highly efficacious in lowering LDL-C.

Downloads

Download data is not yet available.
Published
2018-09-10
Section
Reviews
Keywords:
Cardiovascular prevention, drug therapy, hypercholesterolemia, lipid lowering therapy, cardiometabolic disease.
Statistics
Abstract views: 668

PDF: 344
HTML: 35
Share it

PlumX Metrics

PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.

How to Cite
Vettor, R., & Serra, R. (2018). Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. Italian Journal of Medicine, 12(3), 203-212. https://doi.org/10.4081/itjm.2018.1062